MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. :
MCE 国际站:CX-5461 dihydrochloride
产品活性:CX-5461 dihydrochloride 是一种有效的,可口服的 Pol I 介导的 rRNA synthesis 抑制剂,在 HCT-116,A375 和 MIA PaCa-2 细胞中,IC50 值分别为 142 nM,113 nM 和 54 nM,对 Pol II 作用不大 (IC50 ≥25 μM)。
研究领域:Cell Cycle/DNA Damage
作用靶点:DNA/RNA Synthesis
In Vitro: CX-5461 is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC50s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC50, ≥25 μM). CX-5461 has modest inhibition on DNA replication and protein translation. CX-5461 also exhibits broad antiproliferative activity against a panel of human cancer cell lines, with a mean EC50 of 147 nM, but has minimal effect on viability of nontransformed human cells, with EC50 values of appr 5000 nM. EC50s of CX-5461 for HCT-116, A375, and MIA PaCa-2 cell lines are 167, 58, and 74 nM, respectively. CX-5461 induces autophagy and senescence in solid tumor cancer cells, rather than apoptosis, through a p53-independent process. Eμ-Myc lymphoma cells from tumor-bearing mice are exquisitely sensitive to CX-5461 with an IC50 of 27.3 nM ± 8.1 nM for Pol I transcription after 1 hr and IC50 of 5.4 nM ± 2.1 nM for cell death after 16 hr. CX-5461 activates p53 via the nucleolar stress response in Eμ-MycLymphoma Cells.
In Vivo: CX-5461 displays antitumor activity against human solid tumors in murine xenograft models. CX-5461 (50 mg/kg, p.o.) shows significant MIA PaCa-2 growth inhibition with TGI equal to 69% on day 31 and 79% TGI on A375 on day 32. CX-5461 (50 mg/kg, p.o.) inhibits the Eμ-Myc tumor cells with 84% repression in Pol I transcription at 1 hr posttreatment in C57BL/6 mice. CX-5461 also induces a rapid reduction in tumor burden in the lymph nodes and a concomitant reduction of spleen size to within the normal range.
相关产品:Clinical Compound Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Orally Active Compound Library | Anti-Blood Cancer Compound Library | IBU-DC Phosphoramidite | 2,4-D sodium salt | Thailanstatin D | Carboplatin-d4 | Caracemide | Farudodstat | Ara-ATP | DNA31 | 2'-OMe-Ac-C Phosphoramidite | Dasabuvir | DNA Gyrase-IN-4 | Uridine triphosphate-13C9,15N2 sodium | 5-Methylcytosine | Cidofovir dihydrate | Capecitabine-d11 | Tezacitabine | Mequindox | 5-Methylcytosine-d4 | TH287 hydrochloride | DNA Gyrase-IN-1 | 2'-O-MOE-5-Me-rU | Levofloxacin sodium | GC7 Sulfate | Psammaplin A | hDHODH-IN-2 | Cycloheximide | Lurbinectedin-d3 | Antipain | 2'-Deoxy-2'-fluoro-l-uridine | (S)-Crizotinib
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。